Trevi Therapeutics (TRVI) Earnings Date & Reports

Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC... Show more

Industry: #Pharmaceuticals Major

Get AI intraday signals

A.I. Advisor

published Earnings

TRVI is expected to report earnings to rise 14.44% to -10 cents per share on August 06

Trevi Therapeutics TRVI Stock Earnings Reports

Q2'26

Est.

$-0.10

Q1'26

Missed

by $0.01

Q4'25

Beat

by $0.04

Q3'25

Beat

by $0.02

Q2'25

Beat

by $0.01

The last earnings report on May 05 showed earnings per share of -9 cents, missing the estimate of -7 cents. With 161.52K shares outstanding, the current market capitalization sits at 1.92B.

View a ticker or compare two or three

Compare

TRVI

Setup

Daily Signal:

Description

Gain/Loss:

Interact to see
Advertisement

A.I.Advisor

published price charts

Last 5 trading days

View AI-Driven Trading for TRVI